How Is Edwards Lifesciences’ Stock Performance Compared to Other Medical Device Stocks?

Company Overview - Edwards Lifesciences Corporation, based in Irvine, California, has a market cap of $50.3 billion and specializes in products and technologies for treating advanced cardiovascular diseases, being the leading manufacturer of tissue heart valves and repair products [1][2]. Stock Performance - Edwards Lifesciences' stock reached a 52-week high of $87.40 on November 26 and is currently trading 2.4% below that peak. The stock has gained 4.8% over the past three months, outperforming the iShares U.S. Medical Devices ETF, which increased by 2.4% during the same period [3]. - Year-to-date, the stock has risen by 15.2% and 19.5% over the past 52 weeks, compared to the iShares U.S. Medical Devices ETF's gains of 9% in 2025 and 4.1% over the past year [4]. Financial Performance - In Q3, Edwards Lifesciences reported a 14.7% year-over-year increase in sales to $1.6 billion, exceeding expectations by 3.3%. The adjusted EPS of $0.67 surpassed consensus estimates by 13.6%. Despite these positive results, the stock dropped 1.2% in the trading session following the earnings release on October 30, but rebounded in the subsequent sessions [5]. Competitive Position - Edwards Lifesciences has outperformed its peer Stryker Corporation, which saw a 3.4% gain year-to-date and a 5.1% decline over the past 52 weeks. Among 31 analysts covering the stock, the consensus rating is a "Moderate Buy," with a mean price target of $93.68, indicating a 9.9% upside potential from current levels [6].